Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

Decreased plasma sRAGE levels in COPD: influence of oxygen therapy.

Gopal P, Rutten EP, Dentener MA, Wouters EF, Reynaert NL.

Eur J Clin Invest. 2012 Aug;42(8):807-14. doi: 10.1111/j.1365-2362.2012.02646.x. Epub 2012 Jan 31.

PMID:
22288943
2.

Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD.

Boschetto P, Campo I, Stendardo M, Casimirri E, Tinelli C, Gorrini M, Ceconi C, Fucili A, Potena A, Papi A, Ballerin L, Fabbri LM, Luisetti M.

Eur J Clin Invest. 2013 Jun;43(6):562-9. doi: 10.1111/eci.12079. Epub 2013 Apr 17.

PMID:
23590548
3.

Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study.

Miniati M, Monti S, Basta G, Cocci F, Fornai E, Bottai M.

Respir Res. 2011 Mar 30;12:37. doi: 10.1186/1465-9921-12-37.

4.

Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD.

Gopal P, Reynaert NL, Scheijen JL, Schalkwijk CG, Franssen FM, Wouters EF, Rutten EP.

Respir Res. 2014 Feb 25;15:24. doi: 10.1186/1465-9921-15-24.

5.

Reduced soluble receptor for advanced glycation end-products in COPD.

Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW.

Eur Respir J. 2011 Mar;37(3):516-22. doi: 10.1183/09031936.00029310. Epub 2010 Jul 1.

6.

Soluble receptor for advanced glycation end-products and progression of airway disease.

Iwamoto H, Gao J, Pulkkinen V, Toljamo T, Nieminen P, Mazur W.

BMC Pulm Med. 2014 Apr 24;14:68. doi: 10.1186/1471-2466-14-68.

7.

Plasma advanced glycation end products are decreased in obese children compared with lean controls.

Sebeková K, Somoza V, Jarcusková M, Heidland A, Podracká L.

Int J Pediatr Obes. 2009;4(2):112-8. doi: 10.1080/17477160802248039.

PMID:
18645732
8.

High plasma levels of the soluble receptor for advanced glycation endproducts in patients with symptomatic carotid atherosclerosis.

Basta G, Castagnini M, Del Turco S, Epistolato MC, Righini P, Sangiorgi GM, De Caterina R, Tanganelli P.

Eur J Clin Invest. 2009 Dec;39(12):1065-72. doi: 10.1111/j.1365-2362.2009.02212.x. Epub 2009 Oct 7.

PMID:
19811526
9.

Plasma advanced glycation end-products and skin autofluorescence are increased in COPD.

Gopal P, Reynaert NL, Scheijen JL, Engelen L, Schalkwijk CG, Franssen FM, Wouters EF, Rutten EP.

Eur Respir J. 2014 Feb;43(2):430-8. doi: 10.1183/09031936.00135312. Epub 2013 May 3.

10.

The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction.

Willemsen S, Hartog JW, van Veldhuisen DJ, van der Meer P, Roze JF, Jaarsma T, Schalkwijk C, van der Horst IC, Hillege HL, Voors AA.

Am Heart J. 2012 Nov;164(5):742-749.e3. doi: 10.1016/j.ahj.2012.07.027.

PMID:
23137505
11.

Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts.

Nienhuis HL, de Leeuw K, Bijzet J, Smit A, Schalkwijk CG, Graaff R, Kallenberg CG, Bijl M.

Rheumatology (Oxford). 2008 Oct;47(10):1554-8. doi: 10.1093/rheumatology/ken302. Epub 2008 Aug 13.

12.
13.

Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes.

Yu Y, Hanssen KF, Kalyanaraman V, Chirindel A, Jenkins AJ, Nankervis AJ, Torjesen PA, Scholz H, Henriksen T, Lorentzen B, Garg SK, Menard MK, Hammad SM, Scardo JA, Stanley JR, Wu M, Basu A, Aston CE, Lyons TJ.

BJOG. 2012 Nov;119(12):1512-20. doi: 10.1111/j.1471-0528.2012.03463.x. Epub 2012 Aug 20.

14.

Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.

Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, Natali A, Ferrannini E, Gastaldelli A.

J Clin Endocrinol Metab. 2006 Nov;91(11):4628-34. Epub 2006 Aug 22.

PMID:
16926247
15.

Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients.

Jabaudon M, Futier E, Roszyk L, Chalus E, Guerin R, Petit A, Mrozek S, Perbet S, Cayot-Constantin S, Chartier C, Sapin V, Bazin JE, Constantin JM.

Crit Care Med. 2011 Mar;39(3):480-8. doi: 10.1097/CCM.0b013e318206b3ca.

PMID:
21220996
16.

Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.

Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ.

Diabetologia. 2006 Nov;49(11):2756-62. Epub 2006 Sep 13.

PMID:
16969649
17.

Circulating levels and dietary intake of the advanced glycation end-product marker carboxymethyl lysine in chronic kidney disease patients on conservative predialysis therapy: a pilot study.

Piroddi M, Palazzetti I, Quintaliani G, Pilolli F, Montaldi M, Valentina V, Libetta C, Galli F.

J Ren Nutr. 2011 Jul;21(4):329-39. doi: 10.1053/j.jrn.2010.06.024. Epub 2010 Dec 30.

PMID:
21193322
18.

Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer.

Jiao L, Taylor PR, Weinstein SJ, Graubard BI, Virtamo J, Albanes D, Stolzenberg-Solomon RZ.

Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1430-8. doi: 10.1158/1055-9965.EPI-11-0066. Epub 2011 Apr 28.

19.

Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD).

Leonardis D, Basta G, Mallamaci F, Cutrupi S, Pizzini P, Tripepi R, Tripepi G, De Caterina R, Zoccali C.

Nutr Metab Cardiovasc Dis. 2012 Sep;22(9):748-55. doi: 10.1016/j.numecd.2010.11.008. Epub 2011 Apr 5.

PMID:
21470837
20.
Items per page

Supplemental Content

Write to the Help Desk